封面
市場調查報告書
商品編碼
1535203

降鈣素原檢測市場:各市場區隔規模,佔有率,法律規章,償付,2033年為止的預測

Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日期: | 出版商: GlobalData | 英文 | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

敗血症是一種危及生命的疾病,其特徵是患者對感染的異常反應導致器官功能障礙。降鈣素原測試提供了一種區分細菌和病毒感染並監測抗生素治療有效性的方法。然而,這些測試不僅用於敗血症患者。降鈣素原可用於監測下呼吸道感染 (LRTI)、細菌性肺炎或需要機械通氣的患者的潛在感染。

降鈣素原 (PCT) 測試透過測量 PCT(激素降鈣素的勝?前體)的產生來診斷和監測敗血症。 PCT 因發炎刺激而增加,通常是細菌感染的結果。

本報告提供全球降鈣素原檢測市場相關資料詳細考察,提供市場上競爭情形,SWOT分析,到2033年為止的市場預測,地區,各國的趨勢等資訊。

目錄

已上市的降鈣素原檢測和不斷變化的競爭格局

  • 主要的產業趨勢洞察
  • 降鈣素原檢測的各市場區隔整體市場收益和2015年~2033年的市場展望
  • 件數,平均銷售價格,市場價值相關詳細資料

世界,地區,各國洞察

  • 降鈣素原檢測市場SWOT分析
  • 降鈣素原檢測市場相關競爭動態的洞察和趨勢
  • 各國醫療制度概要
  • 各國償付政策
  • 各國醫療技術相關法規狀況
簡介目錄
Product Code: GDME781MM

Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Sepsis is a life-threatening condition characterized by organ dysfunction caused by a patient's dysregulated response to infection. Procalcitonin testing provides a means for distinguishing bacterial from viral infection and monitoring the efficacy of antibiotic treatment. However, such tests are not used exclusively for sepsis patients. Procalcitonin may be used for patients with Lower Respiratory Tract Infections (LRTI), bacterial Pneumonia, or for monitoring potential infection of patients requiring mechanical ventilation.

Procalcitonin (PCT) Tests are carried out to diagnose and monitor sepsis, by measuring the production of PCT, a peptide precursor of the hormone calcitonin, which increases in response to a pro-inflammatory stimulus, typically as a result of bacterial infection.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Procalcitonin Test and evolving competitive landscape:

  • Insightful review of the key industry trends.
  • Annualized total Procalcitonin Tests market revenue by segment and market outlooks from

2015- 2033.

  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Procalcitonin Tests market.
  • Competitive dynamics insights and trends provided for Procalcitonin Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific MedTech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Thermo Fisher Scientific Inc, Beckman Coulter Inc + Radiometer Medical ApS, F. Hoffmann-La Roche Ltd, bioMerieux SA,Bio-Rad laboratories Inc, Siemens Healthineers AG, DiaSorin SpA, Quidel Corp and Diazyme Laboratories Inc and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Procalcitonin Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
  • Develop business strategies by understanding the trends shaping and driving Procalcitonin Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Procalcitonin Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Procalcitonin Tests market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.